Skip to main content
Clinical Trials/IRCT20200718048129N1
IRCT20200718048129N1RecruitingPhase 3

Evaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatment

Iran University of Medical Sciences0 sites45 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
45

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20 years to 50 years (—)
Sex
All

Inclusion Criteria

  • Patients with definitive diagnosis of COVID19 were hospitalized and treated
  • Patients with COVID19 who still have dyspena and cough two weeks after discharge from the hospital
  • Patients with COVID19 who continue to have lung involvement on CT SCAN two weeks after discharge

Exclusion Criteria

  • Patients with comorbidities such as chronic heart or lung disease before COVID19
  • The need for long-term use of drugs that have an irreversible interaction with the drugs used in the plan.

Investigators

Similar Trials